Reset
Showing 4 of 4 academic articles

Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trial

Andrew D. Leavitt, Johnny Mahlangu, Priyanka Raheja, Emily Symington et al. • Research and Practice in Thrombosis and Haemostasis (2024)

Background: Valoctocogene roxaparvovec, an adeno-associated virus-mediated gene therapy for severe hemophilia A, enables endogenous factor (F)VIII expression and provides bleed protection. Objectives: Determine valoctocogene roxaparvovec du...

DOAJ Open Access (DOAJ) DOI: 10.1016/j.rpth.2024.102615

Evaluation of the SH-SY5Y cell line as an in vitro model for potency testing of a neuropeptide-expressing AAV vector

Jeanette Zanker, Daniela Hüser, Adrien Savy, Sara Lázaro-Petri et al. • Frontiers in Molecular Neuroscience (2023)

Viral vectors have become important tools for basic research and clinical gene therapy over the past years. However, in vitro testing of vector-derived transgene function can be challenging when specific post-translational modifications are...

DOAJ Open Access (DOAJ) DOI: 10.3389/fnmol.2023.1280556